← All indications
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
Drugs by status
Phase 3 trials (7)
Phase 2 trials (59)
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- azacitidine
- saracatinib
- abemaciclib
- sorafenib
- becatecarin
- busulfan
- temsirolimus
- cixutumumab
- dc1 vaccine
- denileukin diftitox
- doxorubicin
- eribulin
- entinostat
- ex vivo-expanded her2-specific t cells
- gemcitabine
- oblimersen sodium
- imatinib
- gti-2040
- her-2 icd peptide
- her-2/neu peptide vaccine
- aldesleukin
- imiquimod
- indoximod
- Filgrastim
- ixabepilone
- pembrolizumab
- palbociclib
- pazopanib
- pemetrexed
- +29 more
Phase 1 trials (25)
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- decitabine
- mifepristone
- afp464
- alvespimycin
- bavituximab
- cilengitide
- dinaciclib
- epirubicin
- msk-2206
- indomethacin
- fowlpox-sargramostim
- recombinant fowlpox-cea(6d)/tricom vaccine
- interleukin-12
- vaccinia-cea(6d)-tricom vaccine
- vaccinia-muc1 vaccine
- pertuzumab
- ganetespib
- veliparib
- antigen pulsed dendritic cells
- erlotinib
- multivitamins
- cisplatin
- omeprazole
- alvocidib
Organizations
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (31)
- Horizon Pharma
- Eisai
- Celgene
- Merck
- Eli Lilly
- GlaxoSmithKline
- Innocrin Pharmaceutical
- Sponsor GmbH
- University of Pennsylvania
- University of Arizona
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Johns Hopkins University
- Northwestern University
- Ohio State University
- North Central Cancer Treatment Group
- Stanford University
- Thomas Jefferson University
- University of Florida
- University of South Florida
- University of Toronto
- Wayne State University
- Mayo Clinic
- University of California, Los Angeles
- Department of Defense
- City of Hope National Medical Center
- University of Texas at Houston
- Yeshiva University
- +1 more
Organization Involved with Phase 1 Indications (14)
- Wyeth
- IRX Therapeutics
- Synta Pharmaceuticals Corp.
- Tapimmune Inc.
- University of Pittsburgh
- Cancer and Leukemia Group B (CALGB)
- Temple University
- New York University
- Providence Health & Services
- Rutgers University
- University of Southern California
- University of Chicago
- Vanderbilt University
- University of Wisconsin
Organization Involved with Other Experimental Indications (2)